Global Pseudomonas Aeruginosa Infection Treatment Market - 2020-2027
|綠色化膿性傳染病治療全球市場：2020-2027 Global Pseudomonas Aeruginosa Infection Treatment Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
The global pseudomonas aeruginosa infection treatment market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infection, pneumonia, and chronic pain. People with low immune system are highly prone to affected by this infection.
The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection is high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.
The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.
The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boosts the demand for newer pseudomonas aeruginosa infection treatment drugs. As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.
In addition, increasing usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving the market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.
The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarity with antibiotics. Increasing funding for research and development are expected to boost the market growth. For instance, in March 2019, Procarta Biosystems, a pharma company, received funding of USD 2 million from the Novo Holdings Repair Impact Fund to develop new therapies. These funds are used for developing novel therapies for the treatment of complicated urinary tract infections (UTIs) associated with pseudomonas aeruginosa infection. Also, in January 2019, CARB-X made an investment for a novel antibiotic for the treatment of serious lung infections caused by a slew of gram-negative bacteria, including pseudomonas aeruginosa.
However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.
The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global pseudomonas aeruginosa infection treatment market in 2019. Combination therapy is used for the patient who has developed resistance property against monotherapy. During this therapy, the combination of different drugs is used to treat bacterial infection. Rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection. According to a research in 2018, published by Nicole Fosse et al., in PLoS One Journal, combination therapy was administered in 42.8%, and remaining 57.2% were treated with monotherapy. As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy. Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.
Based on drug class, the global pseudomonas aeruginosa infection treatment market is segmented into cephalosporin, aminoglycoside, carbapenem, monobactam, and others Among these, the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.
Based on the route of administration, the global pseudomonas aeruginosa infection treatment market has been segmented into oral, nasal, and intravenous. The intravenous segment is expected to dominate the global pseudomonas aeruginosa infection treatment market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most of the physicians prefer the intravenous route for the administration of drugs, as in intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.
North America region is dominating the global pseudomonas aeruginosa infection treatment market accounted for the largest market share in 2019, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. As per the Agency for Healthcare Research and Quality report, 2019, around 1 of every 25 hospitalized patients in the United States are affected with hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contract one of these infections annually. As per the American Association for the Advancement of Science, the proportion of patients with a hospital-acquired infection was 7.9% in 2017, in Canadian Hospitals. As pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries. The U.S. and Canada have a well-developed health care system which encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.
Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, presence of major players and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.
The Asia-Pacific pseudomonas aeruginosa infection treatment market expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets for over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study and of these, about 9,000 have pseudomonas aeruginosa infection.
The global players are manufacturing majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Novartis AG, among others.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pseudomonas aeruginosa infection treatment market globally. For instance,
The global pseudomonas aeruginosa infection treatment market report would provide an access to an approx. 69 market data table, 64 figures and 280 pages.
LIST NOT EXHAUSTIVE